---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-25-000025"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:16:20.864846+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74

## Summary
- Net revenues $170.5M, down from $171.8M in Q1 2024.
- GAAP net income $25.3M ($0.51 diluted EPS) vs $43.2M ($0.81) last year.
- Adjusted non-GAAP net income $36.9M ($0.74 EPS) vs $55.3M ($1.04) prior year.
- CEO cites BAQSIMI and Primatene MIST growth; FDA accepted insulin biosimilar AMP-004 application.
- Company managing resources for efficient operations amid revenue decline.

## SEC filing metadata
- accession: 0001297184-25-000025
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000025/0001297184-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000025/amph-20250507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-25-000025
- JSON: https://secwatch.observer/filing/0001297184-25-000025.json
- Plain text: https://secwatch.observer/filing/0001297184-25-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.